UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 3)

SYNBIOTICS CORPORATION

Common Stock
(Title of Class of Securities)

871566105

Timothy E. Hoberg, Esq.
Taft, Stettinius & Hollister LLP
425 Walnut Street, Suite 1800
Cincinnati, Ohio 45202
(513) 381-2838
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

April 7, 2005
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box o.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on the following pages)

Jerry L. Ruyan

Thomas A. Donelan

Christopher P. Hendy

13

Redwood Holdings, Inc.

                    Redwood Holdings, LLC

14

                    Remington Capital, LLC

Item 3. Source and Amount of Funds or Other Considerations.

Redwood West Coast, LLC held 2,800 shares of Series C Preferred Stock of Synbiotics Corporation pursuant to a Stock Swap Agreement dated October 31, 2002. Under the terms of the Series C Preferred Stock, such stock is convertible at any time into Common Stock by dividing each share of Series C Preferred Stock, valued at $1,000, by the conversion price, which was initially set at $0.12846. On April 7, 2005, Redwood West Coast, LLC converted 1,569 shares of Series C Preferred Stock into 12,215,907 shares of Common Stock.

During the period from March 26, 2003 until the date of this Amendment, the Reporting Persons received shares of Common Stock in lieu of cash dividends on the Series C Preferred Stock in the following amounts on the following dates:

15

Mr. Ruyan disposed of 8,000 shares of Common Stock on January 5, 2004 and 14,000 shares of Common Stock on December 30, 2004 as gifts. On October 30, 2003, Mr. Hendy disposed of 10,000 shares of Common Stock as a gift.

Also, on September 23, 2004, Redwood Holdings, LLC purchased 100 shares of Series C Preferred Stock with funds from working capital and Remington Capital, LLC, an indirect subsidiary of Redwood Holdings, LLC, received a warrant to purchase 250,000 shares of Common Stock with an exercise price of $0.17 per share, in connection with a credit agreement between Remington Capital and Synbiotics.

Item 4. Purpose of Transaction.

The shares of Series C Preferred Stock, which were converted into shares of Common Stock that are the subject of this Schedule 13D, were acquired by Redwood West Coast, LLC pursuant to a Stock Swap Agreement dated October 31, 2002 between Redwood West Coast, LLC and Synbiotics Corporation. Pursuant to the terms of the Stock Swap Agreement, Redwood West Coast, LLC exchanged its 2,800 shares of Series B Preferred Stock of Synbiotics Corporation for 2,800 shares of Series C Preferred Stock of Synbiotics Corporation. These shares are convertible into 21,796,668 shares of Common Stock at any time. On April 7, 2005, Redwood West Coast, LLC converted 1,569 shares of Series C Preferred Stock into 12,215,907 shares of Common Stock. In addition, under certain circumstances as set forth in the Stock Swap Agreement, Redwood West Coast, LLC may be issued additional shares of Series C Preferred Stock by Synbiotics Corporation.

Each share of Series C Preferred Stock is convertible into such number of shares of Common Stock as is determined by dividing each share of Series C Preferred Stock, valued at $1,000, by the conversion price — initially set at $0.12846. The conversion price is subject to adjustment as set forth in the Certificate of Determination, as amended, establishing the Series C Preferred Stock including, without limitation, adjustments for stock splits, dividends and issuances by Synbiotics Corporation of additional shares of its Common Stock at prices below the applicable conversion price.

Holders of Series C Preferred Stock are entitled to vote with the holders of the Common Stock, as a single class, on each matter submitted to the shareholders of Synbiotics Corporation. Each share of Series C Preferred Stock represents that number of votes that equals the number of shares of Common Stock into which such shares of Series C Preferred Stock may be converted at the applicable conversion price. The voting rights granted to the holders of Series C Preferred Stock apply at all times. In addition, holders of Series C Preferred Stock, voting as a single class, have the ability to amend certain terms of such preferred stock. Accordingly, the Reporting Persons are deemed to have shared voting power over all of the shares reflected in this Schedule 13D related to the Series C Preferred Stock.

Redwood West Coast, LLC acquired the Common Stock and Series C Convertible Preferred Stock reflected in this Schedule 13D for purposes of controlling Synbiotics Corporation. Synbiotics Corporation has restructured its Board of Directors so that Redwood West Coast, LLC designees occupy 2 of the 3 seats on its Board. The Redwood West Coast, LLC Board seats are held by Messrs. Hendy and Donelan.

16

Redwood West Coast, LLC may purchase additional shares of Common Stock of Synbiotics Corporation, either in open market or privately negotiated transactions, for the purpose of increasing its ownership percentage of Synbiotics Corporation. Redwood West Coast, LLC notes that Synbiotics Corporation’s auditors have given it a “going concern” opinion because its cash position will not be sufficient to fund its operations and service its debt for the next twelve months if it also pays a $1,000,000 contractual obligation when it becomes due in July 2005. Redwood West Coast, LLC is considering the options that may be available to it and to Synbiotics Corporation with respect to such matters and other possible cash needs of Synbiotics Corporation. This involves, in part, consideration of whether Synbiotics Corporation should seek additional capital and whether the best interests of Synbiotics Corporation and its stockholders would be served by Synbiotics Corporation remaining a publicly held company or by becoming privately held.

Except as set forth above, the Reporting Persons do not have any plans or proposals which relate to or would result in:

Item 5. Interest in Securities of Issuer.

According to its Form 10-K filed with the Securities and Exchange Commission on March 22, 2005, as of March 21, 2005, Synbiotics Corporation had 21,606,126 shares of its Common Stock outstanding. After factoring in the conversion of the shares reported in this Amendment, the remaining 1,231 shares of Series C Preferred Stock held by Redwood West Coast, LLC, the 100 shares of Series C Preferred Stock owned by Redwood Holdings, LLC, the conversion of 150 shares of Series C Preferred Stock held by others and the warrants to acquire 250,000 shares of Common Stock by each of Remington Capital, LLC and Comerica Bank, Redwood West Coast LLC is deemed to beneficially own 44.3% of the outstanding Common Stock of Synbiotics Corporation, Redwood Holdings, LLC is deemed to beneficially own 47.5% of the outstanding Common Stock, Remington Capital is deemed to beneficially own 0.1% of the outstanding Common Stock, and the other Reporting Persons are deemed to beneficially own the following percentages of the outstanding Common Stock:

17

18

Item 7. Material to be filed as Exhibits.

1. Joint Filing Agreement
2. Power of Attorney for Redwood Holdings, LLC
3. Power of Attorney for Remington Capital, LLC

After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned does hereby certify that the information set forth in this statement is true, complete and correct.

19

Exhibit 1

JOINT FILING AGREEMENT

     In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Schedule 13D, Amendment No. 3 (including amendments thereto) with respect to the Series C Preferred Stock and Common Stock of Synbiotics Corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.

April 19, 2005

Exhibit 2

Power of Attorney

     The undersigned, Redwood Holdings, LLC, hereby appoints Timothy E. Hoberg and Patricia O. Lowry, or either of them, as its true and lawful attorney-in-fact to sign on its behalf and to file with the Securities and Exchange Commission any schedules or other filings or amendments thereto made by it pursuant to Section 13(d) of the Securities Exchange Act of 1934 and related to Synbiotics Corporation.

     IN WITNESS WHEREOF, Redwood Holdings, LLC has caused this Power of Attorney to be executed on its behalf this 18th day of April, 2005.

REDWOOD HOLDINGS, LLC

/s/ Thomas A. Donelan

Thomas A. Donelan, Co-Manager

20

Exhibit 3

Power of Attorney

     The undersigned, Remington Capital, LLC, hereby appoints Timothy E. Hoberg and Patricia O. Lowry, or either of them, as its true and lawful attorney-in-fact to sign on its behalf and to file with the Securities and Exchange Commission any schedules or other filings or amendments thereto made by it pursuant to Section 13(d) of the Securities Exchange Act of 1934 and related to Synbiotics Corporation.

     IN WITNESS WHEREOF, Remington Capital, LLC has caused this Power of Attorney to be executed on its behalf this 18^th day of April, 2005.

REMINGTON CAPITAL, LLC

/s/ Jerry L. Ruyan
Jerry L. Ruyan, President

21